Liselotte Hyveled

Liselotte Hyveled has an extensive career in the pharmaceutical industry, currently serving as a Board Member at TriSalus Life Sciences since May 2024, while also holding the position of Chief Patient Officer and Board Member at Novo Nordisk since August 1992. At Novo Nordisk, Liselotte is instrumental in integrating patient needs into the drug development process, overseeing strategic alliances and collaborations, and ensuring compliance across global operations. Previous roles include leadership in clinical operations, trial execution, and research and development, contributing to innovative projects and global strategies. Additionally, Liselotte has served as the Chairman of the Danish Disability Council and held advisory roles within various organizations. An accomplished academic, Liselotte holds multiple degrees including a Master's in Medical Business Strategies from Copenhagen Business School and has completed executive education programs at Harvard Business School and CBS.